Novo Nordisk Cuts GLP-1 Drug Prices
Pharmaceutical giant Novo Nordisk announced significant price reductions for its popular GLP-1 medications, Wegovy and Ozempic, slashing their list prices by 50% and 35% respectively. Effective January 1, 2027, both drugs will cost $675 per month, a strategic move aimed at improving patient access and affordability, particularly for those with high-deductible health plans.